<DOC>
	<DOCNO>NCT00635063</DOCNO>
	<brief_summary>Purpose : The purpose study compare efficacy safety AD 923 widely use current treatment ( MSIR ) management target BTP subject malignancy take stable dose background opioids . The efficacy evaluation criterion design determine whether AD 923 provide superior analgesia compare MSIR measure primary endpoint .</brief_summary>
	<brief_title>A Multicentre Study Evaluate Safety Efficacy AD 923 Comparison MSIR Treatment CBP Subjects</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<criteria>Main The subject male female , least 18 year age . The subject malignancy , receive opioid therapy underlie persistent cancer pain , tolerant opioid therapy . The subject typically 2 6 episode target BTP per day require treatment . The subject life expectancy &gt; 3 month . The subject caregiver easy , reliable access telephone . Main The subject female pregnant lactating . The subject respiratory cardiac condition , opinion investigator , may clinically worsen opioids . The subject allergy AD 923 product excipients , namely : fentanyl , dehydrate alcohol , menthol , saccharin , citrate buffer ; MSIR product excipients , namely : morphine sulphate , lactose ( anhydrous ) , pregelatinized maize starch , povidone , purified water , magnesium stearate , talc , tablet coating . The subject neurological psychiatric disease , opinion investigator , would compromise data collection . The subject uncontrolled rapidly escalate pain . The subject significant laboratory test result , opinion investigator , compromise subject safety conduct study . The subject plan undergo chemotherapy , radiotherapy , surgery treatment period . The exception subject may continue chemotherapy study period , provide expect alter pain state response pain medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Cancer Breakthrough Pain</keyword>
</DOC>